SCHEMBL6085752

SCHEMBL6085752

Cc1cccc2oc(-c3c[nH]nc3-c3ccc(NC(=O)c4csc(-c5ccncc5)n4)cc3)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
LMNA P02545 3/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ROCK1 Q13464 2/20 0.47
CEPT1 Q9Y6K0 1/20 0.46
MAPK1 P28482 2/20 0.46
ROCK2 O75116 2/20 0.45
TDP1 Q9NUW8 2/20 0.44
ATM Q13315 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPY1R P25929 1/20 0.43
NPY2R P49146 1/20 0.43
AGPAT2 O15120 1/20 0.43
IDE P14735 1/20 0.43
MAPK10 P53779 1/20 0.43
IRAK4 Q9NWZ3 4/20 0.42
HPGD P15428 2/20 0.42
TLR7 Q9NYK1 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087310 0.84 MAPT (0.48) MAPTLMNAMEN1KMT2AROCK1
SCHEMBL6085859 0.79 CEPT1 (0.51) MAPTMEN1KMT2ACEPT1AGPAT2
SCHEMBL6203914 0.79 KDM4E (0.52) MAPTLMNAMEN1KMT2AMAPK1
SCHEMBL6085967 0.78 CEPT1 (0.51) MAPTLMNAMEN1KMT2ACEPT1
SCHEMBL6086300 0.77 CEPT1 (0.47) MAPTLMNAMEN1KMT2ACEPT1
SCHEMBL6084017 0.76 CEPT1 (0.52) MAPTCEPT1AGPAT2SMN1; SMN2
SCHEMBL6086493 0.76 CEPT1 (0.48) MAPTMEN1KMT2ACEPT1AGPAT2
SCHEMBL6085513 0.76 CEPT1 (0.58) MAPTCEPT1AGPAT2SMN1; SMN2
SCHEMBL6087191 0.76 CEPT1 (0.51) MAPTLMNACEPT1NPSR1AGPAT2
SCHEMBL6085024 0.75 CEPT1 (0.46) MAPTLMNAMEN1KMT2ACEPT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885LMNA 4688/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.